Tech Company Financing Transactions
TolerRx Funding Round
On 1/3/2003, TolerRx secured $35 million in Series C funding from Skyline Ventures, Genentech and HealthCare Ventures.
Transaction Overview
Company Name
Announced On
1/3/2003
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series C
Investors
Skyline Ventures (Lead Investor) (Yasunori Kaneko)
Proceeds Purpose
The funds obtained will finance the clinical development of its two lead products and the expansion of its research programs, including the TolerMab" antibody platform.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
300 Technology Square 3rd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
TolerRx is a biopharmaceutical company specializing in the discovery and development of therapies that induce and maintain immunological tolerance and reprogram the immune system to treat patients with immune-related diseases
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Ringler
Browse more venture capital transactions:
Prev: 1/2/2003: Raven Biotechnologies venture capital transaction
Next: 1/3/2003: Iomai venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs